CoChat

The augmentative efficacy of second-generation anti-psychotics (SGA) to anti-depressants in treating treatment-resistant depression: a network meta-regression analysis

Open access
Bai, Binru, Li, Yuwei, Chen, Xi, Huang, Jinsong, Chen, Qiaoling, Du, Xinyuan, Huang, Chengfang, Yang, Yi · 2025 · BMC Psychiatry

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.

Abstract

BACKGROUND: To compare the augmentative efficacy of second-generation anti-psychotics (SGA) to anti-depressants in adult patients with treatment-resistant depression (TRD) adjusting follow-up period and explore the underlying"time window"effects of the regimens. METHODS: Databases included Embase, PubMed, Scopus, Cochrane Library and Google Scholars as well as Clinicaltrials.gov from inception to May 15, 2024, for relevant randomized controlled studies (RCTs) were retrieved. The primary endpoint was Montgomery Asberg Depression Rating Scale (MADRS). The secondary endpoint was MADRS response rate. The tertiary endpoints were Clinical Global Impression-severity (CGI-S) and MADRS remission rate. Standard mean difference (SMD) and hazard ratio (HR) were generated by Bayesian network meta-regression (NMR) for pairwise comparisons on dichotomous and consecutive variants, respectively. RESULTS: A total of 23 studies (N = 10679) with 24 augmentation agents were included in the NMR. For the primary endpoint, compared with ADT, aripiprazole 3 - 12 mg/d, brexpiprazole 1 - 3 mg/d, cariprazine 1.5 - 3 mg/d, olanzapine 6 - 12 mg/d and fluoxetine 25 - 50 mg/d combination, and quetiapine XR were significantly effective (SMD ranged from - 0.28 to - 0.114) and their effect sizes were comparable, after adjusting follow-up period, the results resembled the former except for quetiapine XR (SMD = - 0.10, 95%CI: - 0.212 to 0.014). Brexpiprazole 3 mg/d (7.22 weeks), cariprazine 1 - 2 mg/d (2.97 weeks), cariprazine 2-4.5 mg/d (2.81 weeks), cariprazine 3 mg/d (7.16 weeks), olanzapine 6 - 12 mg/d (4.11 weeks) and quetiapine 150 - 300 mg/d (3.89 weeks) showed"time window". For the secondary endpoint, brexpiprazole 3 mg/d and rispridone 0.5 - 3 mg/d was evidently superior to all others (HR ranged from 1.748 to 2.301). For the tertiary endpoints, as for CGI-S, aripiprazole 2 - 20 mg/d, brexpiprazole 2 - 3 mg/d, cariprazine 3 mg/d, olanzapine 6 - 12 mg/d and fluoxetine 25 - 50 mg/d combination, and rispridone 0.5 - 3 mg/d were conspicuously effective compared with ADT (SMD ranged from - 0.438 to - 0.126) and for MADRS remission rate, aripiprazole 2 - 20 mg/d, brexpiprazole 3 mg/d, cariprazine 3 mg/d, rispridone 0.5 - 3 mg/d were conspicuously effective compared with ADT (HR ranged from 0.477 to 3.326). CONCLUSION: Holistically considering each endpoint and corresponding "time window", certain SGAs appeared to be efficient augmentation to anti-depressants for TRD, but aripiprazole was relatively more effective and better tolerated.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12888-025-06783-7

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Flow chart of the screening procedure
Fig. 1 Flow chart of the screening procedureCC BY-NC-ND · PubMed Central
Fig. 2 Network graph of MADRS pairwise comparisons of regimens for second-generation antipsychotics (SGA) augmentation on treatment-resistant depression
Fig. 2 Network graph of MADRS pairwise comparisons of regimens for second-generation antipsychotics (SGA) augmentation on treatment-resistant depressionCC BY-NC-ND · PubMed Central
Fig. 3 Time-effect size curves of MADRS score
Fig. 3 Time-effect size curves of MADRS scoreCC BY-NC-ND · PubMed Central
Fig. 4 Network graph of MADRS response rate pairwise comparisons of regimens for second-generation antipsychotics (SGA) augmentation on treatment-resistant depression
Fig. 4 Network graph of MADRS response rate pairwise comparisons of regimens for second-generation antipsychotics (SGA) augmentation on treatment-resistant depressionCC BY-NC-ND · PubMed Central
Fig. 5 Time-effect size curves of MADRS response rate
Fig. 5 Time-effect size curves of MADRS response rateCC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 49 references

Research works printed but not linked: 1

  1. Fu X e. Report on national mental health development in China (2019–2020). China: Social Sciences Academic Press; 2022.

Metadata

Authors
Bai, B., Li, Y., Chen, X., Huang, J., Chen, Q., Du, X., Huang, C., & Yang, Y.
Affiliations
  • Dalian Medical University (CN)
  • Zhejiang University (CN)
  • Tianjin University of Traditional Chinese Medicine (CN)
  • Sir Run Run Shaw Hospital (CN)
Corresponding author
Bai, Binru
Venue
BMC Psychiatry
Published
2025-04-05
Volume
25
Issue
1
Pages
338-338
ISSN
1471-244X (ISSN-L)
OpenAlex
W4409183640
Cited by
15
References
49
Citations by year
2026: 9 · 2025: 6
FWCI
8.42
Type
journal article
Language
en
Open access
Licence
Locations
  • BMC Psychiatry (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • The Science and Technology Department of Zhejiang Province Foundation (Grant No. LGF20H060016)
  • The Zhejiang Medical and Health Science and Technology Projec (Grant No. 2022+ZDXK-04)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
Keywords
treatment-resistant depression, atypical antipsychotics, antidepressant augmentation, aripiprazole, brexpiprazole, cariprazine, olanzapine, quetiapine, risperidone, fluoxetine
MeSH terms
Antidepressive Agents, Drug Therapy, Combination, Humans, Antipsychotic Agents, Antidepressive Agents, Second-Generation, Depressive Disorder, Treatment-Resistant

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The augmentative efficacy of second-generation anti-psychotics (SGA) to anti-depressants in treating treatment-resistant depression: a network meta-regression analysis. https://app.cochat.ai/papers/10.1186/s12888-025-06783-7
The paper
Bai, B., Li, Y., Chen, X., Huang, J., Chen, Q., Du, X., Huang, C., & Yang, Y. (2025). The augmentative efficacy of second-generation anti-psychotics (SGA) to anti-depressants in treating treatment-resistant depression: a network meta-regression analysis. BMC Psychiatry. https://doi.org/10.1186/s12888-025-06783-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.